0000000000069704

AUTHOR

Sergio Babudieri

0000-0001-7291-8687

showing 21 related works from this author

Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy

2018

Background In 2017, oral direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection became available free of charge for all HCV-RNA-positive patients, irrespective of their fibrosis stage. Aim The aim of this study was to evaluate the characteristics of HCV-related chronic liver disease (CLD) in Italy just before the introduction of DAA therapy. Patients and methods Patients with CLD were enrolled in two national surveys conducted in 2001 and in 2014. The two surveys prospectively enrolled patients aged older than 18 years referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results Out of the 12 564 patie…

MaleCirrhosisTime FactorsAdministration OralHepacivirusmedicine.disease_causeChronic liver diseaseSeverity of Illness Index0302 clinical medicineRisk FactorsOdds RatioPrevalenceMedicine030212 general & internal medicineProspective StudiesMultivariate AnalysiGastroenterologyHealth SurveyMiddle AgedViral LoadItalyRNA Viral030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyLogistic ModelTime FactorGenotypeHepatitis C virusAntiviral AgentsVirus03 medical and health sciencesAge DistributionInternal medicinechronic hepatitis CHumansSex DistributionProtective FactorAgedAntiviral AgentCross-Sectional StudieHepatitis B virusHepaciviruChi-Square DistributionHepatologybusiness.industryRisk Factorchronic liver diseaseBiomarkerOdds ratioHepatitis C AntibodiesHepatitis C ChronicProtective Factorsmedicine.diseaseHealth SurveysConfidence intervaldirect-acting antiviral therapyProspective Studiehepatitis infectionCross-Sectional StudiesLogistic ModelsMultivariate AnalysisEtiologyHepatitis C AntibodiebusinessBiomarkers
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct

Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C rea…

2019

Previous article in issueNext article in issue Introduction: There is a limited documentation about the retreatment of patients failing a recommended NS5A-containing regimen in Italy. Materials & methods: Within the VIRONET-C network, 386 NS5A-failing patients infected with different HCV-genotypes (GT) (GT1a/1b/2a-c/3a-b-g-h/4a-d-n-o-v=93/124/19/112/38) were analyzed. Retreatment of 105 failures was investigated. HCV-resistance-test was performed by Sanger-sequencing. Results: Failures following seven different NS5A-containing regimens were studied: 3D/2D (paritaprevir/ombitasvir ± dasabuvir) ± ribavirin (N = 72/4), daclatasvir/ledipasvir/velpatasvir + sofosbuvir ± ribavirin (N = 105/13…

Resistance testmedicine.medical_specialtyHepatologybusiness.industryGastroenterologyDAA failurVironet C.NS5ARegimenInternal medicinemedicineretreatmentNS5AbusinessDigestive and Liver Disease
researchProduct

Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy

2019

Background: The epidemiology of hepatocellular carcinoma (HCC) is characterized by a dynamical temporal trend of well-established and emerging risk factors. Methods: We evaluated the temporal trend of aetiological factors of HCC over the last two decades in Italy. HCC cases were recruited from two previously published national studies in 1996 and in 2008 and HCC cases were also enlisted from two national surveys in 2001 and in 2014 enrolling consecutive subjects with chronic liver disease (CLD) referring to more than 80 liver units scattered all over the country for a 6-monthperiod. Results: Out of the 9997 subjects with CLD recruited in 2001 and the 2408 recruited in 2014, 3.3% and 5.7% (P…

0301 basic medicineLiver CirrhosisMaleHepatocellular carcinomaPrevalenceHepacivirusSex FactorChronic liver diseaseAntibodies ViralGastroenterology0302 clinical medicineRisk FactorsSurveys and QuestionnairesHBVPrevalenceMedicineAge Factor030212 general & internal medicineProspective Studieseducation.field_of_studyIncidence (epidemiology)IncidenceLiver NeoplasmsAge FactorsGeneral MedicineHepatitis CHepatitis B viruHepatitis BMiddle AgedHepatitis BHepatitis CInfectious DiseasesItalyLiver NeoplasmHepatocellular carcinomaHCVFemaleAlcoholHumanMicrobiology (medical)medicine.medical_specialtyHepatitis B virusCarcinoma HepatocellularLiver Cirrhosi030106 microbiologyPopulation03 medical and health sciencesSex FactorsInternal medicineHumansRisk factoreducationAgedCross-Sectional StudieHepacivirubusiness.industryRisk Factormedicine.diseasedigestive system diseasesProspective StudieCross-Sectional Studiesbusiness
researchProduct

The association between education level and chronic liver disease of any etiology

2020

Abstract Background The potential link between educational level and chronic liver diseases (CLD) were explored using the mortality records of liver cirrhosis, which lack accuracy and are unable to identify the different etiological factors of liver cirrhosis. Information on the association of low educational level with the severity of CLD is lacking. Aim To evaluate the potential association linking education level to etiology and clinical stage of CLD cases. Methods Consecutive enrolment of 11,107 subjects with CLD aged≥18 years prospectively recruited in two national surveys in 2001 and 2014 at one of the participating Italian liver units throughout the country. Subjects were pooled in t…

Liver Cirrhosismedicine.medical_specialtyCirrhosisAlcohol DrinkingLiver CirrhosiDisease030204 cardiovascular system & hematologyEducational settingChronic liver diseaseLogistic regressionChronic disease03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicineHBVInternal MedicinemedicineHumans030212 general & internal medicineStage (cooking)Association (psychology)Non-alcoholic Fatty Liver Disease.business.industryLiver DiseasesLiver DiseaseFatty liverMiddle Agedmedicine.diseaseItalyHCVEtiologyLiver disorderAlcoholbusinessHumanLiver disordersEuropean Journal of Internal Medicine
researchProduct

Current and future challenges in HCV: insights from an Italian experts panel

2017

Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated …

Microbiology (medical)medicine.medical_specialtySettore MED/17 - Malattie InfettiveDisease stagesComorbidityAntiviral AgentsComorbiditiesVirological response03 medical and health sciences0302 clinical medicineComorbidities; DAAs; HCV; Treatment; Microbiology (medical); Infectious DiseasesmedicineHumans030212 general & internal medicineIntensive care medicineDAAHigh rateComorbidities; DAAs; HCV; Treatmentbusiness.industryDAAsGeneral MedicineHepatitis Cmedicine.diseaseHepatitis CVirologyTreatmentInfectious DiseasesItalyTolerabilityComorbidities; DAAs; HCV; Treatment; Comorbidity; Hepatitis C; Humans; Italy; Antiviral AgentsHealthcare settingsHCV030211 gastroenterology & hepatologyComorbiditiebusinessDirect acting
researchProduct

A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.

2022

Abstract Background Although an increase in hepatitis C virus (HCV) prevalence from Northern to Southern Italy has been reported, the burden of asymptomatic individuals in different Italian regions is currently unknown. Methods A probabilistic approach, including a Markov chain for liver disease progression, was applied to estimate current HCV viraemic burden. The model defined prevalence by geographic area using an estimated annual historical HCV incidence by age, treatment rate, and migration rate from the Italian National database. Viraemic infection by age group was estimated for each region by main HCV transmission routes of individuals for stage F0–F3 (i.e. patients without liver cirr…

Antiviral AgentLiver CirrhosisHepaciviruLiver CirrhosiResearchMarkov chainUndiagnosedInfectious and parasitic diseasesRC109-216HepacivirusHepatitis C ChronicModels TheoreticalAntiviral AgentsHepatitis CInfectious DiseasesHCVPrevalenceHumansHepatitis C infectionHumanBMC infectious diseases
researchProduct

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

2017

0301 basic medicinemedicine.medical_specialtyhepacivirusHCV RASTreatment outcomeDrug ResistanceHCV genotypesDrug resistanceBiologyNS5A03 medical and health sciences0302 clinical medicineSecond linedrug resistance viral; humans; retreatment; treatment outcome; antiviral agents; hepacivirus; hepatitis c chronicInternal medicineDrug Resistance Viral; Humans; Retreatment; Treatment Outcome; Antiviral Agents; Hepacivirus; Hepatitis C ChronicDrug Resistance Viralantiviral agentsmedicineViralChronicNS5AhumansHepatologyhepatitis c chronicHepatitis CHepatitis C ChronicSettore MED/07 - Microbiologia e Microbiologia Clinicamedicine.diseaseHepatitis CVirologyHepatology HCV NS5A030104 developmental biologyHCVtreatment outcome030211 gastroenterology & hepatologyretreatmentdrug resistance viral
researchProduct

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

2018

AbstractNatural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mai…

Male0301 basic medicineSofosbuvirHepacivirusDrug Resistancelcsh:MedicineHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyHepatitis C Virus; HCV resistance-testchemistry.chemical_compound0302 clinical medicineGenotypePrevalenceVirallcsh:ScienceHCV resistance-testMultidisciplinarybiologyHepatitis CMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCohortHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyHepatitis C VirusGenotypeHCV RASHepatitis C virus03 medical and health sciencesInternal medicineDrug Resistance ViralmedicineHumansAdult; Aged; Drug Resistance Viral; Female; Hepacivirus; Hepatitis C; Humans; Italy; Male; Middle Aged; Prevalence; Viral Nonstructural Proteins; GenotypeNS5ANS5BAgedbusiness.industrylcsh:RHepatitis C Virus HCV resistance-testbiology.organism_classificationmedicine.disease030104 developmental biologychemistrylcsh:Qbusiness
researchProduct

Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

2017

Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. Abstract BACKGROUND: Previous cross-sectional studies have shown that hepatitis C virus (HCV) infection had been the main agent associated with liver cirrhosis in Italy. AIM: To assess epidemiological, laboratory and clinical features of liver cirrhosis in Italy in 2014. PATIENTS: Out of the 2557 consecutive subjects evaluated in 16 hospitals located throughout Italy in 2014, 832 (32.6%) had liver cirrhosis and were enrolled in this study. RESULTS: The mean age of subjects was 60.3years, with a male/female ratio of 1.7; 74.9% of cases had Child…

MaleCirrhosisSettore MED/09 - Medicina InternaAlcohol abuseAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Internal Medicinemedicine.disease_causeGastroenterology0302 clinical medicineRisk FactorsEpidemiologyHBV030212 general & internal medicineLiver Neoplasmsvirus diseasesMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver NeoplasmHepatocellular carcinomaHCV030211 gastroenterology & hepatologyAlcohol abuse; HBV; HCV; Liver cirrhosis; Liver cirrhosis epidemiology; Aged; Alcoholism; Carcinoma Hepatocellular; Cross-Sectional Studies; Female; Hepatitis B; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Risk Factors; Internal MedicineFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusLiver CirrhosiAlcohol abuseLiver cirrhosis epidemiology03 medical and health sciencesInternal medicinemedicineInternal MedicineHumansDecompensationAgedHepatitis B virusCross-Sectional Studiebusiness.industryRisk FactorCarcinomaHepatocellularmedicine.diseaseCross-Sectional StudiesLiver cirrhosisEtiologybusiness
researchProduct

Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug us…

2011

Abstract The global spread of hepatitis B virus (HBV) and hepatitis C virus (HCV), their high chronicity rates and their progression to cirrhosis and hepatocellular carcinoma, are major public health problems. Research and intervention programmes for special population groups are needed in order to assess their infection risk and set up suitable prevention and control strategies. Aim of this paper is to give health care professionals information on HBV and HCV infections amongst migrants, drug users and prison inmates. The manuscript is an official Position Paper on behalf of the following Scientific Societies: Italian Association for the Study of the Liver (A.I.S.F.), Italian Society of In…

medicine.medical_specialtymedia_common.quotation_subjectHCV HBV vaccimantion inmatesPopulationPsychological interventionPrisonContext (language use)migrantsmedicine.disease_causeVulnerable PopulationsDrug UsersHepatitis B ChronicHealth carehcvMedicineHumanseducationPsychiatrySubstance Abuse Intravenousmedia_commonHepatitis B virusTransients and Migrantseducation.field_of_studyHepatologybusiness.industryPublic healthPrisonersVaccinationGastroenterologyvirus diseasesHepatitis C Chronicintravenous drug usersSocioeconomic FactorsPractice Guidelines as TopichbvPosition paperhbv; hcv; intravenous drug users; migrants; prison inmatesbusinessprison inmates
researchProduct

Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation

2021

Objectives: Optimized diagnostic algorithms to detect active infections are crucial to achieving HCV elimination. We evaluated the cost effectiveness and sustainability of different algorithms for HCV active infection diagnosis, in a context of a high endemic country for HCV infection. Methods: A Markov disease progression model, simulating six diagnostic algorithms in the birth cohort 1969‐1989 over a 10‐year horizon from a healthcare perspective was used. Conventionally diagnosis of active HCV infection is through detection of antibodies (HCV‐Ab) detection followed by HCV‐RNA or HCV core antigen (HCV‐Ag) confirmatory testing either on a second sample or by same sample reflex testing. The …

Pediatricsmedicine.medical_specialtyCost effectivenessCost-Benefit Analysiscost-effectiveneContext (language use)HepacivirusAntiviral AgentsLiver diseaseMedicineHumansbusinesshealth care economics and organizationsHepatologybusiness.industryscreeningDisease progressionHCV chronic infectionvirus diseasesDiagnostic algorithmshealthHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CHcv eliminationdigestive system diseasesWHO targetHcv core antigenbusinessAlgorithms
researchProduct

Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression

2021

Abstract Background The universal treatment of diagnosed patients with chronic HCV infection has been widely conducted in Italy since 2017. However, the pool of individuals diagnosed but yet to be treated in Italy has been estimated to end around 2025, leaving a significant proportion of infected individuals undiagnosed/without care. Estimates of this population are currently unknown. Methods A probabilistic modelling approach was applied to estimate annual historical HCV incident cases by their age-group (0–100 years) distribution from available literature and Italian National database (1952 to October 2019). Viraemic infection rates were modelled on the main infection routes in Italy: peo…

Liver CirrhosisPediatricsBlood transfusionEpidemiologymedicine.medical_treatmentlaw.invention0302 clinical medicineFibrosislawEpidemiologyPrevalence030212 general & internal medicineStage (cooking)ChildSubstance Abuse IntravenousMonte CarloAged 80 and overeducation.field_of_studyMiddle AgedHepatitis CInfectious DiseasesTransmission (mechanics)ItalyChild PreschoolHCVmedicine.symptomModels Theoretical: Young AdultHumanAdultmedicine.medical_specialtySexual transmissionAdolescentLiver Cirrhosi030231 tropical medicinePopulationMarkov chainAntiviral AgentsMicrobiologyAsymptomaticlcsh:Infectious and parasitic diseasesYoung Adult03 medical and health sciencesVirologymedicineHumanslcsh:RC109-216Hepatitis C infectioneducationAgedAntiviral Agentbusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornUndiagnosedInfantModels Theoreticalmedicine.diseaseParasitologybusiness
researchProduct

Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

2014

S. Bruno1, S. Bollani1, A.L. Zignego2, V. Calvaruso3, C. Magni4, S. Landonio4, M. Rizzetto5, A. Ciancio5, A. Mangia6, V. Piazzolla6, M. Caremani7, S. Piovesan8, L. Cavalletto9, S. Babudieri9, A. Moretti 10, C. Colletta11, M. Massari12, S. Fangazio13, F. Mazzotta14, L. Muratori15, A.E. Colombo16, M. Zuin17, A. Traverso18, T. Santantonio19, F. Farina20, E. Marchionne21, G. Serviddio22, M. Russello23, A. Licata24, A. Craxi3, V. Di Marco3 1 Internal Medicine, AO Fatebenefratelli e Oftalmico, Milano, Italy 2 Internal Medicine, Universita di Firenze, Italy 3 Gastroenterology, Universita di Palermo, Italy 4 Infectiuos Diseases, Ospedale Sacco, Milano, Italy 5 Gastroenterology, Universita di Torino…

medicine.medical_specialtyHepatologybusiness.industryInfectious disease (medical specialty)Family medicineGastroenterologymedicinebusinessTreatment experiencedAdvanced fibrosisDigestive and Liver Disease
researchProduct

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens

2017

Background Intracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR). We modeled ALT and HCV-RNA kinetics in cirrhotic patients treated with currently-used all-DAA combinations to evaluate their mode of action and cytotoxicity compared with telaprevir (TVR)+PR. Study design Mathematical modeling of ALT and HCV-RNA kinetics was performed in 111 HCV-1 cirrhotic patients, 81 treated with all-DAA regimens and 30 with TVR+PR. Kinetic-models and Cox-analysis were used to assess determinants of ALT-decay and normalization. Results HCV-RNA kinetics was biphasic, reflecting …

Genetics and Molecular Biology (all)SimeprevirMaleHepacivirusHepacivirusPharmacologyBiochemistryStiffness0302 clinical medicineAnimal CellsMedicineAmino Acidslcsh:ScienceAlanineOrganic CompoundsLiver Diseases3. Good healthCirrhosisPhysical SciencesAdministrationInterferon030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesOligopeptidesHumanOralMaterials ScienceGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansAgedKineticPharmacologyHepaciviruBiochemistry Genetics and Molecular Biology (all)Mathematical Modelinglcsh:RChemical CompoundsBiology and Life SciencesProteinsmedicine.diseasedigestive system diseasesAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)030104 developmental biologyAgricultural and Biological Sciences (all)chemistryAliphatic Amino Acidslcsh:Q0301 basic medicineSofosbuvirlcsh:MedicineAdministration OralMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Viral Nonstructural ProteinsTelaprevirchemistry.chemical_compoundSimeprevirMedicine and Health SciencesViralMultidisciplinarybiologyAntimicrobialsMedicine (all)Simulation and ModelingDrugsAlanine TransaminaseHepatitis CMiddle AgedAntiviralsHepatitis CChemistryTreatment OutcomeLiverCombinationOligopeptideRNA ViralFemaleAnatomymedicine.drugResearch ArticleSettore MED/17 - Malattie InfettiveGeneral Science & TechnologyMaterial PropertiesResearch and Analysis MethodsMicrobial ControlVirologyRibavirinMechanical PropertiesNS5AAntiviral Agentbusiness.industryRibavirinHCV DAA ALTViral Nonstructural ProteinOrganic ChemistryCell Biologybiology.organism_classificationKineticsAlanine transaminaseAdministration Oral; Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Kinetics; Male; Middle Aged; Oligopeptides; RNA Viral; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteinsbiology.proteinHepatocytesRNAInterferonsSofosbuvirbusiness
researchProduct

Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy

2018

Introduction. To evaluate the characteristics of alcohol-related chronic liver disease (CLD) in Italy and their potential changes over time. Patients and Methods. Subjects with CLD were enrolled in two national surveys performed in 2001 and in 2014 in Italy. The two surveys prospectively recruited patients aged ≥ 18 years referring to more than 80 Italian liver units scattered all over the country using similar clinical approach, analytical methods, and threshold of risky alcohol intake definition (≥ 3 units/day in men and ≥ 2 units/day in women). Results. Out of 12,256 enrolled subjects, 2,717 (22.2%) reported a risky alcohol intake. Of them, anti-HCV positive was observed in 48.3% of subj…

Liver CirrhosisMaleCirrhosisChronic liver diseaseHealth Risk BehaviorsHealth Risk BehaviorLiver disease0302 clinical medicineStage (cooking)ChronicLiver DiseasesGastroenterologyGeneral MedicineHepatitis CHealth SurveyMiddle AgedAlcoholicHepatitis CAlcoholismItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleSex ratioAdult; Aged; Alcohol Drinking; Alcoholism; Chronic Disease; Female; Health Risk Behaviors; Health Surveys; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Diseases Alcoholic; Male; Middle AgedResearch ArticleHumanAdultmedicine.medical_specialtyArticle SubjectAlcohol DrinkingLiver Cirrhosi03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Liver Diseases AlcoholicAgedHepatologybusiness.industryHepatologyHepatitis C AntibodiesHepatitis C Chronicmedicine.diseaseHealth SurveysAgeingChronic Diseaselcsh:Diseases of the digestive system. GastroenterologybusinessHepatitis C Antibodie
researchProduct

Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey

2016

The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Background The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Methods We enrolled 2,557 CLD consecutive patients in 16 Italian liver units in 2014. Results HBV etiology accounted for 513 (20.2%) cases, alone in 439 and associated with HCV and/or alcohol abuse in 74. Of these 513, 11.9% were anti-HDV-positive and 7.2% HBeAg-positive. HCV alone was responsible for 50.3% of CLD and with alcohol abuse for 5.9%. HCV RNA was detec…

MaleCirrhosisAlcohol abuseGastroenterology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseSurveys and QuestionnairesEpidemiologyOutpatients80 and overSurveys and QuestionnaireChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Adolescent; Adult; Aged; Aged 80 and over; Alcoholism; Carcinoma Hepatocellular; Female; Genotype; Hepatitis B; Hepatitis C; Humans; Inpatients; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Outpatients; Surveys and Questionnaires; Young Adult; Hepatology; Gastroenterology030212 general & internal medicineYoung adultHCCChronic liver diseasesChronic hepatitisAged 80 and overMedicine (all)Liver NeoplasmsChronic liver diseaseGastroenterologyvirus diseasesOutpatientHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver Neoplasm030211 gastroenterology & hepatologyFemaleInpatientHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentGenotypeLiver CirrhosiChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Medicine (all); Hepatology; Gastroenterology03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedInpatientsHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesLiver cirrhosisEtiologyChronic hepatitibusiness
researchProduct

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

2017

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and w…

Male0301 basic medicinehepatitis C virusSustained Virologic ResponseSofosbuvirHepacivirusDrug ResistanceHepacivirusresistance-associated substitutionsViral Nonstructural ProteinsVARIANTSNS5Amedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrenceINFECTIONantiviral therapyMedicinehepatitis C viruViralTreatment FailureChronicantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; hepatologybiologyGENOTYPE 1virus diseasesMiddle Agedantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutionsSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCombinationInterferonDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAuthor Keywords:antiviral therapyRIBAVIRINSequence AnalysisHumanmedicine.drugmedicine.medical_specialtyDaclatasvirGenotypeHepatitis C virusAntiviral AgentsLONG-TERM PERSISTENCEDACLATASVIR03 medical and health sciencesDrug Therapyantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; Aged; Antiviral Agents; Drug Resistance Viral; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; HepatologyTREATMENT-NAIVEInternal medicineDrug Resistance ViralRibavirinHumansNS5Aresistance testdirect-acting antiviralsAgedAntiviral Agentresistance-associated substitutiondirect-acting antiviralHepaciviruHepatologyresistance test KeyWords Plus:HEPATITIS-C VIRUSbusiness.industryRibavirinViral Nonstructural ProteinSequence Analysis DNADNAHepatitis C ChronicHepatologybiology.organism_classificationClinical trial030104 developmental biologySOFOSBUVIRchemistrySequence AnalysihepatologyMutationImmunologyInterferonsSofosbuvirbusiness
researchProduct

Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study

2017

Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …

MaleTime FactorsCirrhosisSettore MED/09 - Medicina InternaHbv vaccination0302 clinical medicinechronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccinationMedicine030212 general & internal medicineChildAged 80 and overVaccinationMiddle AgedVaccinationInfectious DiseasesItalyLiverCarrier StateFemale030211 gastroenterology & hepatologyHbsag carrierAdultHepatitis B virusAdolescentYoung Adult03 medical and health sciencesHepatitis B ChronicChronic hepatitisVirologyHumansHBsAg-positive chronic hepatitis clinical presentationHepatitis B Vaccineschronic hepatitis BHepatitis B AntibodiesHBsAg-positive chronic hepatitisAgedHBsAg chronic carrierHBV vaccinationImmunization Programsbusiness.industrychronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; virology; infectious diseasesInfantchronic hepatitis B; HBsAg chronic carriers; HBsAg-positive chronic hepatitis; HBsAg-positive chronic hepatitis clinical presentation; HBV vaccination; Virology; Infectious Diseasesmedicine.diseaseVirologyCross-Sectional StudiesHBsAg chronic carriersMulticenter studyHepatitis b vaccinationHBsAg-positive chronic hepatitibusiness
researchProduct

Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy

2017

Background: Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014). Methods: The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results: The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone (11.4% vs. 6.9%), but less likely t…

Alcoholic liver diseasePathologyCirrhosisliver diseasesHepatocellular carcinomaPrevalenceChronic liver diseaseGastroenterology0302 clinical medicinecohort studiesEpidemiologymiddle aged030212 general & internal medicinehumansChronic liver diseasesHBV infectionChronic hepatitisadultChronic liver diseaseGeneral MedicineHepatitis CHepatitis BHCV infectionagedInfectious DiseasesItalyyoung adult030211 gastroenterology & hepatologyCohort studyMicrobiology (medical)medicine.medical_specialtyprevalence03 medical and health sciencesInternal medicinemedicineLiver Diseases AlcoholicAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinoma; Microbiology (medical); Infectious DiseasesAlcoholic liver diseases; Chronic hepatitis; Chronic liver diseases; HBV infection; HCV infection; Hepatocellular carcinomabusiness.industryAlcoholic liver diseaseAlcoholic liver diseasesmedicine.diseaseprospective studiessex factorsChronic hepatitihepatitis Bhepatitis Cbusinesschronic diseasealcoholic liver diseases; chronic hepatitis; chronic liver diseases; HBV infection; HCV infection; hepatocellular carcinoma; adult; aged; chronic disease; cohort studies; hepatitis B; hepatitis C; humans; Italy; liver diseases; liver diseases alcoholic; middle aged; prevalence; prospective studies; sex factors; young adultalcoholic
researchProduct

Additional file 1 of A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different…

2022

Additional file 1: Table S1. Estimates of % of viraemic HCV individuals in different Italian regions according to fibrosis stage and high-risk groups.

researchProduct